What SEC filings does Puma Biotechnology, Inc. submit to the SEC?

Puma Biotechnology, Inc. (PBYI) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about PBYI?

A Form 4 for PBYI discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Puma Biotechnology, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for PBYI?

The 10-K is Puma Biotechnology, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all PBYI SEC filings directly on EDGAR?

You can view all historical Puma Biotechnology, Inc. filings on the SEC EDGAR company page for PBYI. Each filing card on this page links directly to the original SEC document.

How often does Puma Biotechnology, Inc. file with the SEC?

Puma Biotechnology, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling PBYI shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

PBYI SEC Filing News — Puma Biotechnology, Inc.

Latest SEC filings for Puma Biotechnology, Inc. (PBYI) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-16.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A fo…

Sector: Healthcare Industry: Biotechnology Market Cap: $527.0M CIK: 1401667

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for PBYI currently lean bearish. Of the 20 filing records displayed, 10 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

PBYI Filing Activity Snapshot 2026-06-15 — 2026-09-16

Insider Transactions (Form 4)

0 buys vs 10 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$567.0K

Cesano Alessandra (Director) · 2026-09-16

62,150 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 12 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 12 filings in this group are Form 4s for Puma Biotechnology, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 12 insider filings shown, the breakdown is 10 open-market sale and 2 compensation award. 10 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×10: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×2: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Form 4 Open-market sale Insider Selling 2026-09-16

PBYI insider WILSON TROY EDWARD (Director) sold 5,000 shares (~$45.5K)

WILSON TROY EDWARD, listed as Director at PUMA BIOTECHNOLOGY, INC., reported an open-market sale of 5,000 PBYI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	5,000	$9.10	$45.5K

Filing: Form 4 (Insider Transaction) Insider: WILSON TROY EDWARD (Director) Shares: 5,000 Est. Value: $45.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-16

PBYI insider Cesano Alessandra (Director) sold 62,150 shares (~$567.0K)

Cesano Alessandra, listed as Director at PUMA BIOTECHNOLOGY, INC., reported an open-market sale of 62,150 PBYI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	50,000	$2.93	$146.5K
`S`	Open-market sale	62,150	$9.12	$567.0K
`M`	Option exercise derivative · Stock Option	50,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Cesano Alessandra (Director) Shares: 62,150 Est. Value: $567.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-08

PBYI insider AUERBACH ALAN H (Director, President and CEO, 10% Owner) sold 44,058 shares (~$364.1K)

AUERBACH ALAN H, listed as Director, President and CEO, 10% Owner at PUMA BIOTECHNOLOGY, INC., reported an open-market sale of 44,058 PBYI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	44,058	$8.26	$364.1K

Filing: Form 4 (Insider Transaction) Insider: AUERBACH ALAN H (Director, President and CEO, 10% Owner) Shares: 44,058 Est. Value: $364.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-08

PBYI insider HUNT DOUGLAS M (See Remarks) sold 8,460 shares (~$69.9K)

HUNT DOUGLAS M, listed as See Remarks at PUMA BIOTECHNOLOGY, INC., reported an open-market sale of 8,460 PBYI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	8,460	$8.26	$69.9K

Filing: Form 4 (Insider Transaction) Insider: HUNT DOUGLAS M (See Remarks) Shares: 8,460 Est. Value: $69.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-08

PBYI insider NOUGUES MAXIMO F (Chief Financial Officer) sold 9,386 shares (~$77.6K)

NOUGUES MAXIMO F, listed as Chief Financial Officer at PUMA BIOTECHNOLOGY, INC., reported an open-market sale of 9,386 PBYI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	9,386	$8.26	$77.6K

Filing: Form 4 (Insider Transaction) Insider: NOUGUES MAXIMO F (Chief Financial Officer) Shares: 9,386 Est. Value: $77.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-15

PBYI insider WILSON TROY EDWARD (Director) sold 10,800 shares (~$77.7K)

WILSON TROY EDWARD, listed as Director at PUMA BIOTECHNOLOGY, INC., reported an open-market sale of 10,800 PBYI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	27,000	—	—
`S`	Open-market sale	10,800	$7.20	$77.7K

Filing: Form 4 (Insider Transaction) Insider: WILSON TROY EDWARD (Director) Shares: 10,800 Est. Value: $77.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-15

PBYI insider Stuglik Brian M (Director) sold 8,100 shares (~$58.3K)

Stuglik Brian M, listed as Director at PUMA BIOTECHNOLOGY, INC., reported an open-market sale of 8,100 PBYI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	27,000	—	—
`S`	Open-market sale	8,100	$7.20	$58.3K

Filing: Form 4 (Insider Transaction) Insider: Stuglik Brian M (Director) Shares: 8,100 Est. Value: $58.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-15

PBYI insider Senderowicz Adrian (Director) sold 27,000 shares (~$194.3K)

Senderowicz Adrian, listed as Director at PUMA BIOTECHNOLOGY, INC., reported an open-market sale of 27,000 PBYI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	27,000	—	—
`S`	Open-market sale	27,000	$7.20	$194.3K

Filing: Form 4 (Insider Transaction) Insider: Senderowicz Adrian (Director) Shares: 27,000 Est. Value: $194.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

PBYI insider Form 4 filed for equity award, exercise, or tax withholding

MILLER MICHAEL PATRICK (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	27,000	—	—

Filing: Form 4 (Insider Transaction) Insider: MILLER MICHAEL PATRICK (Director) Shares: 27,000

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-15

PBYI insider MOYES JAY M (Director) sold 22,000 shares (~$158.8K)

MOYES JAY M, listed as Director at PUMA BIOTECHNOLOGY, INC., reported an open-market sale of 22,000 PBYI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	27,000	—	—
`S`	Open-market sale	22,000	$7.22	$158.8K

Filing: Form 4 (Insider Transaction) Insider: MOYES JAY M (Director) Shares: 22,000 Est. Value: $158.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-15

PBYI insider Dorval Allison (Director) sold 11,610 shares (~$83.6K)

Dorval Allison, listed as Director at PUMA BIOTECHNOLOGY, INC., reported an open-market sale of 11,610 PBYI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	27,000	—	—
`S`	Open-market sale	11,610	$7.20	$83.6K

Filing: Form 4 (Insider Transaction) Insider: Dorval Allison (Director) Shares: 11,610 Est. Value: $83.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

PBYI insider Form 4 filed for equity award, exercise, or tax withholding

Cesano Alessandra (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	27,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Cesano Alessandra (Director) Shares: 27,000

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 5 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Puma Biotechnology, Inc. has 5 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-14

PBYI Form 144 filed for proposed insider sale by Cesano Alessandra (62,150 shares) ~$565.6K

Cesano Alessandra filed a Form 144 with the SEC indicating intent to sell PBYI (PUMA BIOTECHNOLOGY, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Cesano Alessandra Shares: 62,150 Est. Value: $565.6K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-14

PBYI Form 144 filed for proposed insider sale by WILSON TROY EDWARD (5,000 shares) ~$45.5K

WILSON TROY EDWARD filed a Form 144 with the SEC indicating intent to sell PBYI (PUMA BIOTECHNOLOGY, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: WILSON TROY EDWARD Shares: 5,000 Est. Value: $45.5K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-06

PBYI Form 144 filed for proposed insider sale by AUERBACH ALAN H (44,058 shares) ~$364.0K

AUERBACH ALAN H filed a Form 144 with the SEC indicating intent to sell PBYI (PUMA BIOTECHNOLOGY, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: AUERBACH ALAN H Shares: 44,058 Est. Value: $364.0K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-06

PBYI Form 144 filed for proposed insider sale by HUNT DOUGLAS M (8,460 shares) ~$69.9K

HUNT DOUGLAS M filed a Form 144 with the SEC indicating intent to sell PBYI (PUMA BIOTECHNOLOGY, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: HUNT DOUGLAS M Shares: 8,460 Est. Value: $69.9K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-06

PBYI Form 144 filed for proposed insider sale by NOUGUES MAXIMO F (9,386 shares) ~$77.6K

NOUGUES MAXIMO F filed a Form 144 with the SEC indicating intent to sell PBYI (PUMA BIOTECHNOLOGY, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: NOUGUES MAXIMO F Shares: 9,386 Est. Value: $77.6K

View on SEC EDGAR → Open Filing Document →

Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Puma Biotechnology, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-06

PBYI filed 8-K — material company event

PUMA BIOTECHNOLOGY, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-16

PBYI filed 8-K — material company event

PUMA BIOTECHNOLOGY, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Puma Biotechnology, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

PBYI filed Quarterly Report (10-Q)

PUMA BIOTECHNOLOGY, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Puma Biotechnology, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on PBYI. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — PBYI SEC Filings

More Tools for PBYI

PBYI Full Stock Analysis PBYI Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper PBYI analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the PBYI stock analysis page.

PBYI Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer